IMARC Group, a leading market research company, has recently released a report titled "Neurostimulation Devices Market Report by Stimulation Type (Internal Stimulation, External Stimulation), Device Type (SCS (Spinal Cord Stimulation) Devices, DBS (Deep Brain Stimulation) Devices, SNS (Sacral Nerve Stimulation) Devices, VNS (Vagus Nerve Stimulation) Devices, GES (Gastric Electrical Stimulation) Devices, Transcutaneous Electrical Nerve Stimulation Devices, Transcranial Magnetic Stimulation Devices, and Others), Application (Pain Management, Epilepsy, Essential Tremors, Urinary and Fecal Incontinence, Depression, Dystonia, Parkinson’s Disease, and Others), End-User (Rehabilitation Centers, Hospitals, Medical Clinics, and Others), and Region 2025-2033." The study provides a detailed analysis of the industry, including the global neurostimulation devices market growth, share, trends, and forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Neurostimulation Devices Market Highlights:
- Neurostimulation Devices Market Size: Valued at USD 9.6 Billion in 2024.
- Neurostimulation Devices Market Forecast: The market is expected to reach USD 22.0 Billion by 2033, exhibiting a growth rate of 9.21% during 2025-2033.
- Market Growth: The neurostimulation devices market is experiencing robust growth driven by the aging population and rising prevalence of neurological disorders.
- Technology Integration: Advanced technologies like closed-loop systems, improved battery life, and real-time brain sensing capabilities are transforming therapeutic approaches.
- Regional Leadership: North America dominates the market, supported by well-established healthcare infrastructure and strong research capabilities.
- Clinical Applications: Pain management represents the largest application segment, driven by the need for non-opioid alternatives to address the chronic pain epidemic.
- Key Players: Industry leaders include Medtronic Inc., Boston Scientific Corporation, Nevro Corporation, and NeuroPace Inc., which are pioneering innovative neurostimulation solutions.
- Market Challenges: The need for specialized implantation procedures and ongoing patient management presents both challenges and opportunities for market expansion.
Claim Your Free “Neurostimulation Devices Market” Insights Sample PDF: https://www.imarcgroup.com/neurostimulation-devices-market/requestsample
Our report includes:
- Market Dynamics
- Market Trends and Market Outlook
- Competitive Analysis
- Industry Segmentation
- Strategic Recommendations
Industry Trends and Drivers:
- Rising Burden of Neurological Disorders and Chronic Pain:
The organization of the health system is currently facing the challenge of an unprecedented increase in the prevalence of neurological diseases and chronic pain cases. Recently published works found that people with epilepsy had a 2.19 higher risk of developing Parkinson's disease compared to the general population. Chronic pain is an especially large epidemic with 1 in 4 people affected. Chronic pain affects an estimated 1.5 billion people worldwide. It rises to 36% of people aged 65 years and older. Chronic pain affects one in five adults throughout the United States and creates a large potential market for neurostimulation devices, particularly in patients who have inadequate responses to customary medications or intolerable side effects from long-term medication therapies.
- Breakthrough Technological Innovations:
Neurostimulation is a field advancing rapidly. In January 2024, the United States Food and Drug Administration (FDA) approved Medtronic's Percept RC Deep Brain Stimulation system. It is advanced neuromodulation technology. It is marketed as the smallest and thinnest dual-channel neurostimulator that features proprietary BrainSense technology to sense, record and transmit real-time brain signals to allow the physician to personalize therapy to the patient's changing needs, with a battery life of more than 15 years. The device's battery can quickly recharge from 10% to 90% capacity in less than an hour. In January 2023, the US FDA approved Axonics' R20 neurostimulator for the treatment of chronic urinary incontinence, urinary retention, or fecal incontinence. The R20 device has a battery life of greater than 20 years. Improved closed-loop with miniaturization and longer battery life can increase efficacy and improve patient comfort while reducing repeat surgery.
- Growing Acceptance of Minimally Invasive Therapies:
As the public becomes more aware that long-term opioid use to control pain presents dangers, both patients and providers increase neurostimulation's popularity. Patient advocacy groups and physician organizations continue to educate the public about the benefits of neurostimulation therapies toward their increased use. Neurostimulation has received large media attention due to the testimonials of patients who experienced marked improvement in their quality of life after stimulation. Advantages of a minimally intrusive procedure compared to more intrusive surgery include shorter hospital stays, faster recovery time, and lower risk of surgery. Rising acceptance of neuromodulation therapies and increasing reimbursement coverage by different government and private payers across the globe is driving the growth of the global neuromodulation devices market. Government agencies, health care institutions and organizations of experts and researchers, and manufacturers are working to promote the appropriate and optimal use of neuromodulation.
- Aging Population and Healthcare Infrastructure Development:
The growing elderly population is mainly responsible for the growth in the market for neurostimulation devices, as several epidemiological studies have found that the prevalence of chronic pain increases with age, from 12% among 18 to 29-year-old adults to 36% among 65 years old and older. Parkinson's Disease affects almost a million Americans and at least 60,000 new cases get a diagnosis each year. In the United States, epilepsy affects about 2.9 million adults. The US population ages and is more prone to develop movement disorders, feel chronic pain, and contract various other diseases of the nervous system with possible benefit from neurostimulation. This upgrade of aging healthcare infrastructures in parallel generates a more conducive environment for uptake of advanced medical technologies. The well-established healthcare systems in North America, as well as the availability of specialized centers in neurology and prestige research institutions, support innovation and rapid uptake of advanced neurostimulation technologies. The regulatory environment for developed markets is generally conducive to common adoption, while developing markets are gradually showing capabilities to offer this advanced form of therapy.
Neurostimulation Devices Market Report Segmentation:
Breakup by Stimulation Type:
- Internal Stimulation
- External Stimulation
Internal stimulation devices dominate the market due to their superior efficacy in managing complex neurological disorders through targeted, implantable solutions that deliver precise electrical stimulation directly to specific neural structures.
Breakup by Device Type:
- SCS (Spinal Cord Stimulation) Devices
- DBS (Deep Brain Stimulation) Devices
- SNS (Sacral Nerve Stimulation) Devices
- VNS (Vagus Nerve Stimulation) Devices
- GES (Gastric Electrical Stimulation) Devices
- Transcutaneous Electrical Nerve Stimulation Devices
- Transcranial Magnetic Stimulation Devices
- Others
SCS (Spinal Cord Stimulation) devices represent the largest segment, driven by the chronic pain epidemic and the minimally invasive nature of spinal cord stimulation procedures that offer customizable programming to target specific pain areas.
Breakup by Application:
- Pain Management
- Epilepsy
- Essential Tremors
- Urinary and Fecal Incontinence
- Depression
- Dystonia
- Parkinson's Disease
- Others
Pain management dominates the market as neurostimulation devices provide promising alternatives to opioid medications, with technologies like spinal cord stimulation and peripheral nerve stimulation demonstrating remarkable efficacy in treating chronic neuropathic pain, failed back surgery syndrome, and complex regional pain syndrome.
Breakup by End-User:
- Rehabilitation Centers
- Hospitals
- Medical Clinics
- Others
Hospitals lead the market with the largest share, reflecting their central role in diagnosis, treatment, and management of neurological disorders, along with access to multidisciplinary medical teams and state-of-the-art facilities required for safe and effective neurostimulation device implantation and ongoing patient management.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America dominates the market, driven by well-established healthcare infrastructure, advanced medical research capabilities, high prevalence of neurological disorders and chronic pain conditions, favorable reimbursement policies, and supportive regulatory frameworks that encourage innovation and adoption of cutting-edge neurostimulation technologies.
Who are the key players operating in the industry?
The report covers the major market players including:
- Biocontrol Medical
- Boston Scientific Corporation
- Cyberonics Inc.
- Medtronic Inc.
- Neuronetics Inc.
- Neuropace Inc.
- Neurosigma Inc.
- Nevro Corporation
- ST. Jude Medical Inc.
- Synapse Biomedical Inc.
Ask Analyst For Request Customization: https://www.imarcgroup.com/request?type=reportid=1892flag=E
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1–201971–6302
